Enter your contact details & our Business Development
expert will circle back to address your request!
The global sciatica market size was valued at USD 6,000 million in 2021 and is projected to reach around USD 9,200 million in 2030 exhibiting a CAGR of 4.8% in the forecasted period. The increasing awareness about sciatica, increasing incidence and prevalence of sciatica, strong pipeline of products are the significant factors that boost the growth of the global sciatica market. However, side effects of drugs used in the treatment of sciatica, low healthcare budgets being pushed yearly into healthcare sector particularly in emerging and underdeveloped nations along with less awareness on advanced pharmaceutical therapeutics is projected to hinder the market growth.
The increasing awareness about sciatica is boosting the growth of the sciatica treatment market. Awareness about the condition is growing due to efforts by government and non-governmental administrations. For example, HCA Healthcare UK teaches people about symptoms, screening and diagnosis, and potential treatment selections for sciatica in the UK. Also, myDr.com.au, an Australian healthcare website, offers relevant evidence about numerous health-related problems. Additionally, OrthoInfo, the American Academy of Orthopaedic Surgeons (AAOS) patient education site, educates awareness about sciatica, through courses, videos, and animations, in the US.
With the growing COVID-19 cases globally, healthcare services distracted all revenues toward patients suffering from COVID-19 illness. Although COVID-19 strictly affects the respiratory system, it has been reported to show effects on the musculoskeletal system too. Low back pain is among the most general symptoms for which patients require medical examination. A study issued in the Journal of Pain Research in 2021 exhibited that after hospital discharge, 27.3% of post-COVID-19 individuals stated joint pain and 21.7% chest pain. Over, it was emphasized that four weeks after release from the hospital, 10–20% of patients treated in the ward suffered from myalgia, though the percentage augmented to up 30% in those who required intensive care unit (ICU) hospitalization. According to an article by Dr. Mehul Garala 2020, it is assumed that 80% of the people will get low back pain at some point in life, and it also has a high reappearance rate. The pain does not continuously have to be correlated to physical activity, such as lifting, and can occur instinctively, such as when waking up in the morning. Providentially, the most of low back pain episodes can resolve with time.
The non-steroidal anti-inflammatory drug segment holds a major share of the market during the forecasted period. The main antipyretic, anti‐inflammatory, and analgesic effect of NSAIDs is built on the suppression of the cyclooxygenase (COX)‐1 and COX‐2 enzymes. By hindering the COX enzymes, vasodilation is abridged and inflammation released.
Non-steroidal anti‐inflammatory drugs (NSAIDs) are among the most regularly prescribed drugs for the dealing of sciatica. The products are receiving approvals and thus, generating lucrative opportunities in the market. According to sciaticapain.co.uk, 2022, pain killers stop the production of these cells, and the brain stops signalling that there is pain somewhere in the body. Pain killers and anti-inflammatory medications are the most active medicines that make up the most several group of drugs. Most generally, antirheumatics (painkillers) are used to treat pain, muscle pain, fever, and other musculoskeletal disorders. Doctors acclaim low-dose medications that can be obtained over the counter, such as Ibuprofen or Tylenol. The over-the-counter NSAIDs are intended to provide pain relief. Prescription NSAIDs may be essential for pain relief if over-the-counter drugs are unproductive.
As per the type, the acute sciatica segment produced the highest revenue in 2021, and is anticipated to maintain its governance during the forecasted period. This is attributed to growing onset of the disease and increase in awareness for acute sciatica. Acute sciatic is called as latest onset of pain in sciatic nerve for period of four to eight weeks and pain can be self-managed by people via pain medications.
North America is anticipated to hold a significant market share in the global Sciatica market owing to the increase in the elderly population and rising prevalence of lower back pain in this region. According to a study issued by National Center for Health Statistics, in 2021, about 39% of adults in the United States indicated they had experienced back pain in the last three months. A larger number of orthopaedic procedures owing to higher healthcare penetration in the United States and Canada boosts the sciatica market. The great concentration of the most hospitals in the established nations of this region, along with good compensation rates, is totalling boost to the market growth. Furthermore, the large share of surgical processes, particularly sciatica treatment, in the revenues of hospitals favours the market. Back pain is one of the most common kinds of pain between adults in the United States. Such pain can be triggered by strained muscles or ligaments, extra weight, poor posture, emotional problems, or daily activities.
The United States is among the most affected nations across the globe, as there are higher figures of patients suffering from Sciatica and greater in the North America as the patient population is growing associated to other nations due to which North America region is anticipated to occupy a substantial share in the sciatica market over the estimated period.
Additionally, the growing elderly population of the region is anticipated to have a substantial impact on the growth of the considered market as the elder population is more susceptible to pain and other musculoskeletal disorders. For instance, as per the 2021 article of the United States Census Bureau, over 54 million people of age 65 years and more were living in the nation in 2020 and this number is projected to reach 85.7 million by 2050, which will be about 20% of the total population of the United States. Moreover, high expenditure on healthcare, especially in the United States and Canada, along with augmented awareness about the disease, is fuelling the growth of the complete regional market to a large extent. Hence, owing to the above-mentioned factors, the North American region is projected to hold a substantial share in the sciatica market over the forecasted period.
Key Companies Insights
The market for sciatica is moderately competitive. With the rising applications of Sciatica, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Sciatica market, ultimately boosting the market growth. Some of the key companies working in the global Sciatica market include:
• Sorrento Therapeutics
• Eliem Therapeutics
• Scilex Holding
• Sinfonia Biotherapeutics
• Vita Science
• Novartis AG
• Endo Pharmaceuticals
• Omega Laser Systems Ltd.
• Teva Pharmaceutical Industries
• Omron Healthcare, Inc.
• Nidd Valley
• Other players
Some of the Recent Developments:
• In March 2022, Scilex Holding Company, subsidiary of Sorrento Therapeutics, Inc., declared final results for SP-102 (SEMDEXA) efficiency and safety from its essential Phase III clinical trial program for Sciatica pain management. SP-102 (SEMDEXA) validated pain relief that continuous through 12 weeks.
• In December 2021, the United States Food and Drug Administration (FDA) allowed Fast Track title to SP-102 (injectable dexamethasone sodium phosphate viscous gel) for the management of lumbosacral radicular pain or sciatica.
• Acute Sciatica
• Chronic Sciatica
• Non-Steroidal anti inflammatory drug (NSAIDs)
By End User
• Specialty Clinics
• North America
o South Korea
• Latin America
o South Africa
o Saudi Arabia
Please fill form below:
99 WALL STREET #2124 NEW YORK, NY 10005